Xbrane Biopharma Q1 2024: Approaching an eventful second half of the year - Redeye

Redeye returns with a research update following Xbrane’s Q1 report. Sales and EBIT were lower than we had estimated, but end-customer sales grew 30%. The report prompts minor adjustments to our forecasts and valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1008709/xbrane-biopharma-q1-2024-approaching-a-very-eventful-h2?utm_source=finwire&utm_medium=RSS